GNLY

Granulysin

PDB rendering based on 1l9l.
Identifiers
Symbols GNLY; 519; D2S69E; LAG-2; LAG2; NKG5; TLA519
External IDs OMIM188855 HomoloGene117711 GeneCards: GNLY Gene
RNA expression pattern
More reference expression data
Orthologs
Species Human Mouse
Entrez 10578 n/a
Ensembl ENSG00000115523 n/a
UniProt P22749 n/a
RefSeq (mRNA) NM_006433.3 n/a
RefSeq (protein) NP_006424.2 n/a
Location (UCSC) Chr 2:
85.91 – 85.93 Mb
n/a
PubMed search [1] n/a

Granulysin, also known as GNLY, is a protein which in humans is encoded by the GNLY gene.[1]

Function

Granulysin is a protein present in cytotoxic granules of cytotoxic T cells and natural killer cells. Granulysin is a member of the saposin-like protein (SAPLIP) family and is released from cytotoxic T cells upon antigen stimulation. Granulysin has antimicrobial activity against M. tuberculosis and other organisms. Granulysin is alternatively spliced, resulting in the NKG5 and 519 transcripts.[1]

Granulysin is a cytolytic and proinflammatory molecule first identified by a screen for genes expressed “late” (3-5 days) after activation of human peripheral blood mononuclear cells.[2] Granulysin is present in cytolytic granules of cytotoxic T lymphocytes (CTL) and natural killer (NK) cells. Granulysin is made as a 15 kD molecule, and a portion of it is cleaved at both the amino and carboxy termini into a 9 kD form. The 9 kD form is released by receptor-mediated granule exocytosis while the 15 kD form is constitutively secreted. Recombinant 9 kD granulysin is broadly cytolytic against tumors and microbes, including gram positive and gram negative bacteria, fungi/yeast and parasites.[3] 9kD granulysin is also a chemoattractant for T lymphocytes, monocytes, and other inflammatory cells and activates the expression of a number of cytokines, including RANTES, MCP-1, MCP-3, MIP-1α, IL-10, IL-1, IL-6 and IFNα.[4] Mice do not have a granulysin homolog, but transgenic mice expressing human granulysin have been engineered.[5] Granulysin has been implicated in a myriad of diseases including infection, cancer, transplantation, autoimmunity, skin and reproductive maladies.[6]

References

  1. ^ a b "Entrez Gene: GNLY granulysin". http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=10578. 
  2. ^ Jongstra J, Schall TJ, Dyer BJ, Clayberger C, Jorgensen J, Davis MM, Krensky AM (March 1987). "The isolation and sequence of a novel gene from a human functional T cell line". J. Exp. Med. 165 (3): 601–14. doi:10.1084/jem.165.3.601. PMC 2188281. PMID 2434598. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2188281. 
  3. ^ Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, Ganz T, Thoma-Uszynski S, Melián A, Bogdan C, Porcelli SA, Bloom BR, Krensky AM, Modlin RL (October 1998). "An antimicrobial activity of cytolytic T cells mediated by granulysin". Science 282 (5386): 121–5. doi:10.1126/science.282.5386.121. PMID 9756476. 
  4. ^ Deng A, Chen S, Li Q, Lyu SC, Clayberger C, Krensky AM (May 2005). "Granulysin, a cytolytic molecule, is also a chemoattractant and proinflammatory activator". J. Immunol. 174 (9): 5243–8. PMID 15843520. http://www.jimmunol.org/cgi/content/abstract/174/9/5243. 
  5. ^ Huang LP, Lyu SC, Clayberger C, Krensky AM (January 2007). "Granulysin-Mediated Tumor Rejection in Transgenic Mice". J. Immunol. 178 (1): 77–84. PMC 2664664. PMID 17182542. http://www.jimmunol.org/cgi/content/full/178/1/77. 
  6. ^ Krensky AM, Clayberger C (March 2009). "Biology and clinical relevance of granulysin". Tissue Antigens 73 (3): 193–8. doi:10.1111/j.1399-0039.2008.01218.x. PMC 2679253. PMID 19254247. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2679253. 

Further reading